RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company focused on developing targeted oncology therapies and commercializing the FDA-cleared RenovoCath device, recently showcased its latest pre-clinical data at the 2025 Society of Interventional Oncology Annual Conference (SIO 2025) in Las Vegas, Nevada. The abstract presentation highlighted promising findings from RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform, which is designed to optimize localized and targeted drug delivery for challenging-to-treat cancers.
Breaking Barriers in Drug Delivery: Trans-Arterial Micro-Perfusion
The abstract, titled “Micro-CT imaging following intra-arterial delivery of a radiopaque silicone polymer using a double-balloon occlusion catheter in pigs: a model to analyze tissue penetration via the trans-arterial micro perfusion (TAMP) technique,” was presented on February 3, 2025, by Dr. Paula Novelli of the University of Pittsburgh Medical Center.
This study aimed to assess an optimized drug delivery method for tumors with limited blood supply and poor drug penetration. Using a porcine (pig) model and micro-CT imaging, researchers monitored the penetration of therapeutic agents delivered via the TAMP technique.
Key Findings: Enhanced Localized Drug Delivery
The pre-clinical data suggests that the combination of the FDA-cleared RenovoCath dual-balloon device and TAMP therapy could enhance localized drug delivery by increasing drug penetration into the microvasculature surrounding the tumor. The technique allows for controlled blood vessel occlusion by adjusting the distance between the catheter’s occlusion balloons, effectively isolating the treatment area while minimizing off-target effects. Micro-CT imaging confirmed that drug penetration in the targeted tissue was significantly improved compared to traditional drug delivery methods.
Additionally, findings indicate that pre-treatment with radiation may further enhance drug penetration, potentially leading to improved treatment efficacy. The ability to precisely isolate and deliver therapeutics to the tumor site could be a significant advancement for patients with tumors that are typically resistant to treatment, such as pancreatic adenocarcinoma.
Expert Insights: Advancing Cancer Treatment
“This study highlights that TAMP is a promising approach for improving localized drug delivery to challenging tumor sites,” said Dr. Ramtin Agah, Founder, Chairman of the Board, and Chief Medical Officer of RenovoRx. “By refining our understanding of tissue penetration and optimizing infusion techniques, we can enhance clinical outcomes for patients with hypovascular tumors. We are also pursuing further research into radiation-based treatment synergies, which may enhance the therapeutic potential of this platform. Our goal is to revolutionize interventional oncology by providing oncologists with more targeted and effective treatment options.”
The study’s methodology involved utilizing a porcine model to simulate clinical conditions. Researchers inflated the RenovoCath device’s balloons in key arterial locations, including the splenic artery, superior mesenteric artery, and renal artery. This approach facilitated precise side branch exclusion and enhanced microvascular perfusion. Micro-CT imaging revealed extensive filling of microvessels in the targeted areas when compared to control groups where the balloons were left deflated, underscoring the effectiveness of the TAMP technique in drug delivery.
Commercialization and Future Applications
RenovoRx CEO Shaun Bagai emphasized the importance of these findings, stating, “We are excited to showcase this pre-clinical data at SIO 2025. Over the past several years, oncologists and interventional radiologists have used RenovoCath in more than 500 procedures, including clinical trials, for intra-arterial drug delivery. This extensive use underscores the value of our approach in improving targeted cancer treatments.”
Bagai further announced that RenovoRx has launched efforts to commercialize RenovoCath as a stand-alone device. The FDA-cleared device is now being positioned for use in temporary vessel occlusion in various applications, including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. These efforts reflect growing confidence in the device’s ability to enhance therapeutic outcomes for oncology patients.
Panel Discussion: Expanding Clinical Understanding
The potential of the TAMP therapy platform was also a key focus of a panel discussion at SIO 2025, titled “Breaking Barriers in Drug Delivery: Trans-Arterial Micro-Perfusion.” Experts in interventional oncology, including Dr. Novelli, Dr. Khashayar Farsad (Oregon Health and Science University), and Dr. David Sperling (Columbia University Irving Medical Center), shared their experiences and insights on the application of TAMP in clinical practice. The discussion underscored the importance of continued research and innovation in targeted drug delivery to improve RenovoRx treatment outcomes for patients with difficult-to-treat malignancies.
